Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD20 Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT01880567
What this trial is testing

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Who this might be right for
CCND1 PositiveCCND2 PositiveCCND3 Positive+4 more
M.D. Anderson Cancer Center 113
Testing effectiveness (Phase 2)Study completedNCT01682044
What this trial is testing

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Who this might be right for
Contiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular LymphomaContiguous Stage II Grade 3 Follicular Lymphoma+30 more
Roswell Park Cancer Institute 20
Early research (Phase 1)Study completedNCT00788684
What this trial is testing

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Who this might be right for
CD20-Positive Lymphoid MalignanciesChronic Lymphoid LeukemiaHematological Malignancies+1 more
AbbVie 29
Early research (Phase 1)UnknownNCT05155839
What this trial is testing

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Shanghai Miracogen Inc. 108
Early research (Phase 1)Ended earlyNCT06248086
What this trial is testing

Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Who this might be right for
B-cell Lymphoma
Astellas Pharma Global Development, Inc. 1
Early research (Phase 1)Ended earlyNCT03670888
What this trial is testing

Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

Who this might be right for
B Cell Lymphoma
JHL Biotech, Inc. 1
Large-scale testing (Phase 3)Ended earlyNCT01659099
What this trial is testing

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma CD20 Positive
The Lymphoma Academic Research Organisation 671
Testing effectiveness (Phase 2)Study completedNCT02584920
What this trial is testing

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

Who this might be right for
B-cell Non Hodgkin's Lymphoma
Shanghai Henlius Biotech 87
Early research (Phase 1)Active Not RecruitingNCT05737628
What this trial is testing

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Who this might be right for
Lymphoma
Byondis B.V. 17
Testing effectiveness (Phase 2)Study completedNCT00169195
What this trial is testing

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Who this might be right for
Diffuse Large Cell Lymphoma
Lymphoma Study Association 49
Testing effectiveness (Phase 2)Ended earlyNCT00089284
What this trial is testing

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Who this might be right for
Non-Hodgkin's Lymphoma (NHL)
Northwestern University 30
Testing effectiveness (Phase 2)Study completedNCT00169143
What this trial is testing

Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma

Who this might be right for
Untreated CD20-positive Large B-cell Lymphoma
Lymphoma Study Association 60
Testing effectiveness (Phase 2)Study completedNCT02042391
What this trial is testing

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy

Who this might be right for
Posttransplant Lymphoproliferative Disorder
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH 60
Large-scale testing (Phase 3)WithdrawnNCT04671420
What this trial is testing

Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.

Who this might be right for
CD20-positive Follicular Lymphoma, With Low Tumour Burden
Shanghai Henlius Biotech
Large-scale testing (Phase 3)UnknownNCT03777085
What this trial is testing

Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 230
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07035379
What this trial is testing

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)
Zhejiang Teruisi Pharmaceutical Inc. 66
Early research (Phase 1)UnknownNCT03980379
What this trial is testing

Pharmacokinetics, Efficacy and Safety of the 304 Injection

Who this might be right for
CD20 Positive B Cell NHL
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 60
Large-scale testing (Phase 3)Ended earlyNCT00169169
What this trial is testing

Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

Who this might be right for
CD20-Positive Large B-Cell Lymphoma
Lymphoma Study Association 430
Early research (Phase 1)Study completedNCT03332121
What this trial is testing

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

Who this might be right for
CD20 Positive B Cell Non-Hodgkin's Lymphoma
Shanghai Pharmaceuticals Holding Co., Ltd 30
Testing effectiveness (Phase 2)Ended earlyNCT04074330
What this trial is testing

TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
Takeda 38
Next Page